Observations placeholder
Sirolimus
Identifier
020033
Type of Spiritual Experience
Background
A description of the experience
Sirolimus (INN/USAN), also known as rapamycin, is a macrolide (one of a group of drugs containing a macrolide ring) produced by the bacterium Streptomyces hygroscopicus It has immunosuppressant functions in humans and is used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B cells by inhibiting the production of interleukin-2 (IL-2). Sirolimus is also used as a coronary stent coating.
Adverse effects
Lung toxicity
Lung toxicity is a serious complication associated with sirolimus therapy, especially in the case of lung transplants. The mechanism of the interstitial pneumonitis caused by sirolimus and other macrolide MTOR inhibitors is unclear, and may have nothing to do with the mTOR pathway. The interstitial pneumonitis is not dose-dependent, but is more common in patients with underlying lung disease.
Lowered effectiveness of immune system
There have been warnings about the use of sirolimus (Rapamune) in liver transplants, where it is suspected to increase mortality due to increase of infections
Cancer risk
As with all immunosuppressive medications, in theory, sirolimus may decrease the body's inherent anticancer activity and allow some cancers that would have been naturally destroyed to proliferate. Patients on immunosuppressive medications have a 10- to 100-fold increased risk of cancer compared to the general population. Historically, about 10% of solid organ recipients treated with calcineurin inhibitors develop skin tumours and lymphoma after 70 months. However, data are contradictory regarding calcineurin inhibitors versus sirolimus via UV-induced carcinogenesis-associated processes such as DNA repair, and p53 and MMP expression as a result from different biochemical mechanisms. People who currently have or have already been treated for cancer have a higher rate of tumor progression and recurrence than patients with an intact immune system. These general considerations counsel caution when exploring the potential of sirolimus to combat cancer.
Diabetes-like symptoms
Sirolimus inhibits a protein kinase complex known as mTORC1. Sirolimus also acts on a related complex known as mTORC2. Disruption of mTORC2 produces the diabetes-like symptoms of decreased glucose tolerance and insensitivity to insulin also associated with sirolimus. Treatment with sirolimus may also increase the risk of type 2 diabetes
On Dec, 23, 2016 2,988 people reported to have side effects when taking Sirolimus.
Among them, 6 people (0.2%) have Hallucination
Time on Sirolimus when people have Hallucination :
| n/a |
Gender of people who have Hallucination when taking Sirolimus :
| Female | Male | |
| Hallucination | 0.00% | 100.00% |
Age of people who have Hallucination when taking Sirolimus :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Hallucination | 0.00% | 0.00% | 0.00% | 0.00% | 50.00% | 0.00% | 50.00% | 0.00% |
On Feb, 8, 2016: 1,895 people reported to have side effects when taking Sirolimus. Among them, 53 people (2.80%) have Death.
Time on Sirolimus when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 78.95% | 0.00% | 10.53% | 0.00% | 10.53% | 0.00% | 0.00% |
Gender of people who have Death when taking Sirolimus :
| Female | Male | |
| Death | 45.45% | 54.55% |
Age of people who have Death when taking Sirolimus :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.00% | 0.00% | 15.91% | 6.82% | 20.45% | 22.73% | 34.09% |